Wave Life Sciences (WVE) EBITDA (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of EBITDA data on file, last reported at -$73.8 million in Q2 2026.

• Quarterly EBITDA fell 39.89% year-over-year to -$73.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$217.9 million (down 51.85% YoY) and the FY2025 annual result came in at -$215.4 million, down 95.09% from the prior year.
• EBITDA slipped to -$73.8 million in Q2 2026, from -$31.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $23.0 million in Q4 2024 to a low of -$73.8 million in Q2 2026.
• A 5-year average of -$36.8 million and a median of -$38.5 million in 2022 frame the typical range for EBITDA.
• The widest YoY moves for EBITDA: up 222.94% in 2024, down 1538.23% in 2024.
• Tracing WVE's EBITDA over 5 years: stood at -$43.6 million in 2022, then jumped by 57.11% to -$18.7 million in 2023, then jumped by 222.94% to $23.0 million in 2024, then slumped by 345.86% to -$56.5 million in 2025, then sank by 30.7% to -$73.8 million in 2026.
• The last three EBITDA figures came in at -$73.8 million (Q2 2026), -$31.3 million (Q1 2026), and -$56.5 million (Q4 2025), per Business Quant data.